Blood immune cells as potential biomarkers predicting relapse-free survival of stage III/IV resected melanoma patients treated with peptide-based vaccination and interferon-alpha

INTRODUCTION: Despite the recent approval of several therapies in the adjuvant setting of melanoma, tumor relapse still occurs in a significant number of completely resected stage III-IV patients. In this context, the use of cancer vaccines is still relevant and may increase the response to immune c...

Descripción completa

Detalles Bibliográficos
Autores principales: Moschella, Federica, Buccione, Carla, Ruspantini, Irene, Castiello, Luciano, Rozo Gonzalez, Andrea, Iacobone, Floriana, Ferraresi, Virginia, Palermo, Belinda, Nisticò, Paola, Belardelli, Filippo, Proietti, Enrico, Macchia, Iole, Urbani, Francesca
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233106/
https://www.ncbi.nlm.nih.gov/pubmed/37274275
http://dx.doi.org/10.3389/fonc.2023.1145667

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10233106/
https://www.ncbi.nlm.nih.gov/pubmed/37274275
http://dx.doi.org/10.3389/fonc.2023.1145667

Ejemplares similares